Michael W. Bonney
Known title: DirectorCIK: 0001219016
Associated companies
this person other insiders at THQ
Transaction History
| ALNY | ▲ Buy | Option Exercise | 11,250 | $790K | 8/18/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 11,250 | $5.1M | 8/18/2025 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 11,250 | $1.5M | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 431 | $117K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 301 | $83K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,263 | $350K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 549 | $147K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 729 | $196K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 245 | $66K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 660 | $180K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 882 | $241K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,239 | $344K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 432 | $121K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 372 | $105K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 802 | $226K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,617 | $459K | 5/15/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,728 | $489K | 5/15/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 30,000 | $2.9M | 12/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 30,000 | $5.8M | 12/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,535 | $284K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,714 | $319K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,389 | $260K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 450 | $84K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 500 | $91K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 560 | $103K | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 300 | $54K | 8/3/2023 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 22,477 | $0 | 8/2/2023 | View on chart |
| THW | ▲ Buy | Open Market | 10,917 | $200K | 8/17/2015 | View on chart |
| THQ | ▲ Buy | Open Market | 5,000 | $100K | 7/28/2014 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.